EFFICACY OF BISOPROLOL-EUTHYROX-ROSUVASTATIN COMBINATION IN ATRIAL
FIBRILLATION AGAINST THE BACKGROUND OF HYPOTHYROIDISM AND DYSLIPIDEMIA

Rakhmatullov Fagim Kasymovich, Doctor of medical sciences, professor, head of the sub-department of internal diseases, Medical Institute, Penza State University (40 Krasnaya street, Penza, Russia), pgu-vb2004@mail.ru
Zinovyeva Elena Grigoryevna, Candidate of medical sciences, head of cardiological unit № 1, Municipal clinical emergency hospital named after G. A. Zacharyin (7 Stasova street, Penza, Russia), alivzi@yandex.ru
Grachyova Julia Nikolaevna, Applicant, sub-department of internal diseases, Medical Institute, Penza State University (40 Krasnaya street, Penza, Russia); cardiologist, clinical diagnostic center "Mediclinic" (7b Stasova street, Penza, Russia) , pgu-vb2004@mail.ru
Bibarsova Alia Muhamedzhanovna, Candidate of medical sciences, associate professor, sub-department of internal diseases, Medical Institute, Penza State University (40 Krasnaya street, Penza, Russia), pgu-vb2004@mail.ru

616.12-008.313-85

Background. The article aims at analyzing the efficacy of Bisoprolol-Euthyrox-Rosuvastatin combination in treating atrial fibrillation when exertional angina is combined with subclinical hypothyroidism and dyslipidemia.
Materials and methods. The study involved the following methods: echocardiography, thyroid ultrasound, Holter monitoring, assessment of thyroid hormone level and blood lipid spectrum.
Results. The authors analyzed the way Bisoprolol-Euthyrox-Rosuvastatin combination influences thyroid volume and function, cardiac hemody-namic/electrophysiological parameters, the number and duration of paroxysmal atrial fibrillation episodes when exertional angina is combined with subclinical hypothyroidism and dyslipidemia.
Conclusions. The research findings suggest that Bi-soprolol-Euthyrox-Rosuvastatin combination is a promising option to treat patients with paroxysmal AF when exertional angina is combined with subclinical hypothyroidism and dyslipidemia.

atrial fibrillation, hypothyroidism, dyslipidemia, Euthyrox, Rosuvas-tatin, Bisoprolol.

1. Kakuchaya T. T. Annaly aritmologii [Arrhythmology annals]. 2005, no. 1, p. 36.
2. Young-Xu Y., Blatt C., Bedell S. J. Amer. Coll. Cardiol. 2003, vol. 41, no. 301A, pp. 1122–1181.
3. Rakhmatullov F. K., Zinov'eva E. G., Gracheva Yu. N. et al. Molodezh' i nauka: mo-dernizatsiya i innovatsionnoe razvitie strany: II Mezhdunarod. nauch.-prakt. konf. studentov i molodykh uchenykh [Youth and science: modernization and innovative devel-opment of the country: II International scientific and practical conference of students and young scientists]. Penza, 2012, pp. 326–329.
4. Aronov D. M. Kardiologiya [Cardiology]. 2008, no. 8, pp. 60–68.
5. Aronov D. M. Lechashchiy vrach [Doctor in charge]. 2006, no. 9, pp. 40–44.
6. Balabolkin M. I., Klebanova E. M., Kreminskaya V. M. Fundamental'naya i klinicheskaya tiroidologiya (rukovodstvo) [Fundamental and clinical thyriodology (guide)]. Moscow: Meditsina, 2007, 816 p.
7. Shiller N. B., Osipov M. A. Klinicheskaya ekhokardiografiya [Clinical echocardiography]. Moscow: Praktika, 2005.
8. Oganov R. G., Aronov D. M., Bubnova M. G. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular therapy and preventive measures]. 2006, no. 6, pp. 95–107.
9. La Rosa J. C., Grundy S. M., Waters D. D. et al N. Engl. Med. 2005, vol. 352, pp. 1425–1435.
10. Anderson K. P. J. Amer. Coll. Cardiol. 2003, vol. 42, pp. 88–92.
11. Chung-Wah Siu., Lau Chu-Pak, Tse Hung-fat Am. J. of Cardiol. 2003, vol. 92, pp. 1343–1345.
12. Barton M., Kiowski W. Curr Hepertens Rep. 2001, vol. 3, pp. 322–330.
13. Wassmann S., Laufs U., Muller K. Arterioscler. Thromb. Vasc. Biol. 2002, vol. 22, pp. 300–305.
14. Dernellis J., Panaretou C. Acta Cardiol. 2001, vol. 56, pp. 375–380.
15. Akahane T., Mizushige K., Nishio H. et al. Heart Vessels. 2003, vol. 18, pp. 157–159.